As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance for ...

The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name of ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new dual-antibody treatment shows promise against Respiratory Syncytial Virus (RSV), a ...

The mRESVAX RSV vaccine from Moderna is being tested to protect newborns via vaccination of pregnant women, with large phase 3 data informing the program. This product is driving the price of Moderna ...

Moderna’s mRESVAX aims to protect newborns from RSV before they even take their first breath. The maternal vaccine candidate is one of the quieter projects in Moderna’s mRNA pipeline – but it targets ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older. A study analyzing data from October 2016 to September ...

Although RSV is a frequent cause of acute respiratory infections (ARIs), an estimation of its incidence has proven challenging due to a lack of routine testing, overlapping clinical presentations with ...